Company intelligence / Profile preview

Protagonist Therapeutics, Inc.

Newark, California, United States of Americaprotagonist-inc.com ↗

Ownership: Public · PTGX
Employees: ~126
Development stage: Phase 3

Overview

Protagonist has two lead candidates in Phase 3 clinical trials: Rusfertide for polycythemia vera (met primary endpoint in VERIFY trial) and Icotrokinra (JNJ-2113) for plaque psoriasis. Both are expected to file NDAs with the FDA in 2025. The company also has several earlier-stage programs in development.

Therapeutic areas: GastroenterologyRheumatologyEndocrinologyDermatologyHematology
Modalities: Peptide-based therapeuticsPeptide mimeticsOral peptides
Industry: Biotech

Drug pipeline

10 assets

rusfertide

Approved

9 more assets in the full pipeline.

Request access →

Partnerships

Takeda PharmaceuticalsJanssen Biotech (Johnson & Johnson)

Financials

Market cap: $9.3B
Total revenue: $213.5M
Enterprise value: $8.6B

Beyond the preview

Go deeper on Protagonist Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protagonist Therapeutics, Inc..

Explore the full profile